[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628324":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":99,"centralContacts":104,"locations":112,"responsibleParty":125,"collaborators":127,"id":131,"slug":132,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":133,"sex":139,"minAge":140,"maxAge":35,"enrollmentInfo":141,"targetDuration":35,"studyType":144,"phases":145,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":115,"whyStopped":35,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Northumbria Healthcare NHS Foundation Trust","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Structured Health Assessment","ACTIVE_COMPARATOR","Structured Health Assessment\n\n1. Confirm (or exclude) the COPD diagnosis and measure study outcomes\n2. Identify and treat pulmonary, extra-pulmonary and modifiable behaviour traits\n3. Perform a comprehensive multi-morbidity assessment\n4. Deliver targeted educational interventions",[13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29],"Diagnostic Test: Sputum sample","Diagnostic Test: Venepuncture","Diagnostic Test: Lung function test","Diagnostic Test: Medical history and physical examination","Diagnostic Test: Blood pressure","Diagnostic Test: BMI","Radiation: HRCT of chest","Diagnostic Test: ECG","Diagnostic Test: Echo","Diagnostic Test: Subject Questionnaires","Diagnostic Test: Research Questionnaires","Biological: Influenza Vaccines","Biological: Pneumococcal Vaccine","Biological: RSV F vaccine (0.5mL injection)","Diagnostic Test: Oxygen saturation (+\u002F- ABG)","Radiation: DXA","Behavioral: Education",[31,36,40,44,47,50,54,59,63,67,71,75,80,83,86,90,94],{"type":32,"name":33,"description":33,"armGroupLabels":34,"otherNames":35},"DIAGNOSTIC_TEST","Sputum sample",[9],null,{"type":32,"name":37,"description":38,"armGroupLabels":39,"otherNames":35},"Venepuncture","FBC, Total IgE, Corrected Calcium, Vitamin D, Liver function test, Early morning cortisol, HbA1C, NT pro BNP, Lipid panel, U\\&E",[9],{"type":32,"name":41,"description":42,"armGroupLabels":43,"otherNames":35},"Lung function test","Spirometry, FENO +\u002F- Gas transfer, body plethysmography",[9],{"type":32,"name":45,"description":45,"armGroupLabels":46,"otherNames":35},"Medical history and physical examination",[9],{"type":32,"name":48,"description":48,"armGroupLabels":49,"otherNames":35},"Blood pressure",[9],{"type":32,"name":51,"description":52,"armGroupLabels":53,"otherNames":35},"BMI","Weight and height Waste and hip circumference",[9],{"type":55,"name":56,"description":57,"armGroupLabels":58,"otherNames":35},"RADIATION","HRCT of chest","HRCT of chest (Strat X protocol) with coronary artery caclium score",[9],{"type":32,"name":60,"description":61,"armGroupLabels":62,"otherNames":35},"ECG","Electrocardiogram",[9],{"type":32,"name":64,"description":65,"armGroupLabels":66,"otherNames":35},"Echo","Echocardiogram",[9],{"type":32,"name":68,"description":69,"armGroupLabels":70,"otherNames":35},"Subject Questionnaires","Clinical questionnaires: ESS, FRAX score, QRISK4,",[9],{"type":32,"name":72,"description":73,"armGroupLabels":74,"otherNames":35},"Research Questionnaires","Research questionnaires: eMRCD, SQRQ-C, EQ-5D-5L, HADS-A, HADS-D, Seven step inhaler technique, PIH scale",[9],{"type":76,"name":77,"description":78,"armGroupLabels":79,"otherNames":35},"BIOLOGICAL","Influenza Vaccines","For those eligible under usual standard of care",[9],{"type":76,"name":81,"description":78,"armGroupLabels":82,"otherNames":35},"Pneumococcal Vaccine",[9],{"type":76,"name":84,"description":78,"armGroupLabels":85,"otherNames":35},"RSV F vaccine (0.5mL injection)",[9],{"type":32,"name":87,"description":88,"armGroupLabels":89,"otherNames":35},"Oxygen saturation (+\u002F- ABG)","Resting oxygen saturation on room air (+\u002F- ABG)",[9],{"type":55,"name":91,"description":92,"armGroupLabels":93,"otherNames":35},"DXA","Participants with a high or intermediate FRAX® risk score, or those aged \\>50 years with a history of fragility fractures, will be offered a dual-energy x-ray absorptiometry scan (DXA)",[9],{"type":95,"name":96,"description":97,"armGroupLabels":98,"otherNames":35},"BEHAVIORAL","Education","Education on Inhaler Technique, Medication Adherence, Tobacco \\& Substance Abuse, Physical Activity, and COPD Self Management",[9],[100],{"name":101,"affiliation":102,"role":103},"Ruth E Sobala, MBBS","Northumbria Healthcare Foundation NHS Trust","PRINCIPAL_INVESTIGATOR",[105,109],{"name":101,"role":106,"phone":107,"phoneExt":35,"email":108},"CONTACT","+44191 293 4351","ruth.sobala2@northumbria-healthcare.nhs.uk",{"name":110,"role":106,"phone":107,"phoneExt":35,"email":111},"Stephen C Bourke","stephen.bourke@northumbria-healthcare.nhs.uk",[113],{"facility":114,"status":115,"city":116,"state":35,"zip":35,"country":117,"countryCode":118,"cosmosGeoPoint":119,"geoPoint":124,"contacts":35},"Northumbria NHS Foundation Trust","RECRUITING","North Shields","United Kingdom","UK",{"type":120,"coordinates":121},"Point",[122,123],-1.44925,55.01646,{"lat":123,"lon":122},{"type":126,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[128],{"name":129,"class":130},"AstraZeneca","INDUSTRY","100628324","structured-review-to-optimise-management-and-prevent-harm-in-copd-100628324",false,"NCT07460154","Structured Review: To Optimise Management and Prevent Harm in COPD","A Structured Health Assessment in Frequent COPD Exacerbators: To Optimise Management, Identify Comorbidities and Prevent Oral Corticosteroid Related Harm","STOPMYCOPD","Inclusion Criteria\n\n1. COPD diagnosis documented in primary care records for at least 12 months.\n2. Age 35 years or older\n3. 3 or more prednisolone prescriptions in the past 12-months for ECOPD\\*\n4. Capacity to give informed consent\n5. Clinically stable at study entry (≥4 weeks following last ECOPD or other significant acute illness) \\* each prednisolone course separated by a minimum of 14 days from completion of the previous course.\n\nExclusion Criteria\n\n1. Maintenance OCS use currently or within the past 12 months \\*\n2. Anticipated inability to comply with the protocol\n3. Illness limiting life expectancy to less than 12 months (other than COPD)\n4. Housebound\n5. Lung transplant\n6. Domiciliary non-invasive ventilation \\*defined as ≥10mg daily for ≥ 6 weeks","ALL","35 Years",{"count":142,"type":143},96,"ESTIMATED","INTERVENTIONAL",[146],"NA","Background:\n\nChronic obstructive pulmonary disease (COPD) is a serious lung condition and the third leading cause of death worldwide. People with COPD have sudden and distressing flare-ups (exacerbations). These can be triggered by infections or occur without a clear cause. Flare-ups often lead to hospital admission, can cause a lasting health decline, increase the risk of dying and are strongly liked to lower income.\n\nSometimes, people are wrongly diagnosed with COPD, when they have a different health issue. Other diseases (like heart conditions) are common in people with COPD, and share similar symptoms. These have often not been diagnosed and worsening of these conditions can look like a flare-up of COPD, leading to incorrect treatment. Additionally, many people with COPD have not been offered appropriate treatments that would reduce their flare-up frequency.\n\nCOPD flare-ups are treated with steroid tablets (prednisolone), and sometimes antibiotics. Frequent use of prednisolone causes side effects such as weight gain, bone thinning (osteoporosis) and diabetes. Reducing how often people with COPD have flare-ups can reduce these side effects.\n\nThe investigators aim to reduce COPD flare-ups and prevent harm from prednisolone by improving the treatment of COPD, while also checking for other health conditions.\n\nThe goal:\n\nIn people with COPD, who take prednisolone for flare-ups (three of more times a year), the investigators want to see if a thorough assessment (that focuses on the treatment of COPD and diagnosis of other common health problems), reduces the number of flare-ups that need prednisolone over the next year.\n\nDesign:\n\nParticipants will attend a half-day hospital visit for a thorough check-up (a mini-MOT). The assessment includes a review by a doctor, questionnaires, blood tests, breathing tests, a scan of the chest (CT), and investigations on the heart. The investigators will make sure participants receive the correct treatment for their COPD.\n\nThe assessment will focus on three areas: lung health, identifying and treating important health issues outside of the lungs (that may be contributing or causing symptoms similar to COPD) and supporting changes in behaviours that can improve lung health. These factors (whether in the lungs, body or related to lifestyle) are known as treatable traits.\n\nThe investigators will also review participants prednisolone use and check for health problems that may have been caused by it. At the end of the assessment participants will be given a personalised treatment plan.\n\nParticipants will be followed up for 12 months, at 3 month intervals. During this time they will collect information on the number of emergency hospital visits, serious heart-related events, steroid tablets taken for COPD flare-ups and any deaths. They will ask participants to complete short questionnaires about their health and wellbeing.\n\nWho provided advise on this study :\n\nPreventing COPD flare-ups is a top priority, identified by The James Lind Alliance (a national research priority setting partnership). This study was reviewed by the Northumbria Lung Research Patient Advisory Group (people living with COPD). They felt the study was well-designed and likely to make a meaningful difference. People with experience in research and COPD also gave feedback, and changes were made, such as reducing travel requirements, based on their views. The research team has successfully completed studies that have led to real improvement in COPD care, and are committed to ensuring this study has a similar positive impact.\n\nSharing results:\n\nAt the end of the study results will be shared with the public, study participants, healthcare workers, commissioners and guideline advisory groups. The findings will be shared on online platforms, present them at national\u002Finternational conferences, and published in medical journals. The aim is to ensure findings improve clinical practice, policies and guidelines.",[149],"COPD",[149,151,152,153,154,155,156,157,158],"Structured assessment","Treatable Trait","Complex Intervention","Exaceration","Steroid","Oral Corticosteroid","Comorbidity","Multimorbity","2026-04-20",{"date":161,"type":162},"2026-04-23","ACTUAL",{"date":164,"type":162},"2026-03-11",{"date":166,"type":143},"2029-03-02",{"name":5,"class":6},1]